IMP A SDB logo

Implantica AG Stock Price

OM:IMP A SDB Community·SEK 16.5b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

IMP A SDB Share Price Performance

SEK 58.30
16.75 (40.31%)
SEK 58.30
16.75 (40.31%)
Price SEK 58.30

IMP A SDB Community Narratives

There are no narratives available yet.

Snowflake Analysis

Flawless balance sheet with slight risk.

4 Risks
1 Reward

Implantica AG Key Details

€2.0m

Revenue

€3.0m

Cost of Revenue

-€1.0m

Gross Profit

€18.7m

Other Expenses

-€19.7m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-0.07
-52.90%
-994.66%
0%
View Full Analysis

About IMP A SDB

Founded
2015
Employees
50
CEO
Peter Forsell
WebsiteView website
www.implantica.com

Implantica AG engages in the research and distribution of medical implants in Switzerland. The company’s lead product candidate is RefluxStop, a passive CE-marked implant for prevention of gastroesophageal reflux disease. It focuses on two treatment areas, Gastrointestinal surgery and Urology. It is also involved in the development of eHealth platform, a digital health system to support its pipeline of smart medical implants designed for a safe and secure control and monitoring over the internet; e-InVivo, a sensor implants to monitor a multitude of health parameters and provide diagnostic information, as well as control treatment from inside the body; wireless energizing platform; and AppetiteControl, an implant to treat obesity by controlling appetite. In addition, the company develops UriControl, a hand pumped artificial urinary sphincter to treat urinary incontinence for men and women; and UriRestor, a remote-controlled device that enables spinal cord injury and multiple sclerosis patients to urinate on demand using the wireless platform. Further, it provides PotencyFlow for treatment of erectile dysfunction; StomaRestore for eliminating stoma bags; RectalRestore for treatment of fecal incontinence; and AneurysmControl for monitoring the expansion of the aneurysms. The company was founded in 2015 and is based in Vaduz, Liechtenstein.

Recent IMP A SDB News & Updates

Recent updates

No updates